ADC Therapeutics SA filed an 8-K press release on November 2, 2026, disclosing a grant of options to purchase 17,000 common shares to a new employee under its Inducement Plan.

Key Highlights

  • Options granted: An aggregate of 17,000 common shares subject to purchase options were granted to a single new employee on November 2, 2026.
  • Purpose: The grant was described as a "material inducement to the employee's employment," according to the filing.
  • Approval authority: The Compensation Committee of the Board of Directors approved the grant pursuant to the Company's Inducement Plan.
  • Regulatory basis: The grant was made in reliance on the employment inducement exemption under NYSE Listed Company Manual Rule 303A.08.
  • Vesting schedule: 25% vests on the first anniversary of the grant date, then 1/48th of the aggregate shares vest on each monthly anniversary thereafter, with full vesting on the fourth anniversary, subject to continued employment.

ADC Therapeutics Inducement Option Grant Details: November 2, 2026

ADC Therapeutics SA (NYSE:ADCT), headquartered in Lausanne, Switzerland, announced on November 2, 2026, that it had made an option grant covering 17,000 common shares to a new employee. According to the filing, the grant was issued as a "material inducement to the employee's employment" and was approved by the Compensation Committee of the Company's Board of Directors under the Company's Inducement Plan.

The filing states the grant was made in reliance on the employment inducement exemption provided under NYSE Listed Company Manual Rule 303A.08, and the press release was issued by the Company pursuant to that same rule. The Inducement Plan is described in the filing as designed "to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company."

Regarding the vesting terms, the filing specifies that 25% of the options will vest and become exercisable on the first anniversary of the grant date, with 1/48th of the aggregate number of shares vesting on each monthly anniversary of the grant date thereafter, so that the full award is vested as of the fourth anniversary of the grant date. Vesting is subject to continued employment with the Company. No exercise price for the options was stated in the filing text.

What Was Disclosed

The filing disclosed an inducement option grant of 17,000 common shares to a new employee, approved by the Compensation Committee under the Company's Inducement Plan and NYSE Rule 303A.08, with a four-year vesting schedule beginning November 2, 2026.